相关实验视频

Updated: Jul 22, 2025

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

作为针对阿尔茨海默氏症疾病的多目标导向联结体的昆林特里-塔克林混合体

Elisa Uliassi¹, Christian Bergamini¹, Nicola Rizzardi¹

¹Department of Pharmacy and Biotechnology, Alma Mater Studiorum - University of Bologna, 40126 Bologna, Italy.

Bioorganic & medicinal chemistry

|July 24, 2023

概括

研究人员通过修改一个状杂交体,开发了针对阿尔茨海默病 (AD) 的新型多目标导向配体 (MTDLs). 这些新化合物,特别是混合3号,具有强大的酶抑制,抗氧化活性和抗粉样蛋白特性,显示出有前途,这表明AD药物发现的新脚手架.

科学领域:

药用化学医学化学
神经科学是一个神经科学.
药理学药理学是指药理学的学科.

背景情况:

阿尔茨海默病 (AD) 病理包括一个复杂的网络,需要多目标药物发现方法.
多重目标导向联结体 (MTDLs) 提供了一个有前途的策略,可以同时调节多个AD目标.
塔克林是一种乙胆酶抑制剂,作为开发具有扩展抗老年痴呆特征的新型MTDLs的基础.

研究的目的:

通过修改先前开发的塔克林-农混合体来设计和合成针对AD的新型MTDL.
评估林基基架作为抗AD药物发现的新动机的潜力.
评估新混合物在抑制胆酶酶,表现出抗氧化作用和防止粉样蛋白聚合方面的有效性.

主要方法:

塔克林与2,5,8-氨酸基架的分子杂交,以创建新的MTDL (化合物2-6).
在体外评估胆化酶抑制.
评估SH-SY5Y细胞在梅纳迪诱导的氧化应激下抗氧化活性.
对抗粉样蛋白聚合特性和肝毒性的评估.

主要成果:

新型MTDLs,特别是混合型3,在纳米分子度下表现出强大的胆酶抑制作用.
混合3在细胞氧化应激模型中表现出显著的抗氧化作用.
化合物3显示出有利的抗粉样蛋白聚合特性和低肝毒性.
奇诺林特里支架成为开发抗粉样蛋白聚合和抗氧化剂的有希望的动机.

结论:

开发的塔克林-林基因混合体代表了一种新的MTDL类,具有治疗阿尔茨海默病的潜力.
混合3显示出一个有前途的多目标配置文件,包括酶抑制,抗氧化活性和抗粉胺聚合效应.
在阿尔茨海默氏病药物发现中,金利尼基基架被确定为未来MTDL设计的有价值的结构动机.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.粉样蛋白-β 是一种胆化酶酶的使用方法多目标导向的带多目标导向的带.多种药理学多种药理学奇诺林氨酸 (quinolinetrione) 是一种氨酸.塔克里因是指一个神经元.

更多相关视频

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Published on: February 4, 2017

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...